Heart therapy

摘要

A new treatment for heart failure with the "potential to change clinical practice" could save the lives of 20% more patients than the current gold-standard therapy, according to the results of a large clinical trial. The results were so compelling that the trial -known as PARADIQM-HF and published in The New England Journal of Medicine (online, 30 August 2014)-was called to a halt seven months before it was due to finish. Researchers reported an "overwhelming benefit" from the investigational treatment compared with enalapril, the widely used angiotensin-converting enzyme (ACE) inhibitor.